- Home
- COCO vs DNLI Comparison
COCO vs DNLI Comparison
Compare COCO & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COCO | DNLI |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.7B |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | COCO | DNLI |
|---|---|---|
| Price | $65.37 | $24.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $57.75 | $34.33 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.60 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.12 | N/A |
| Revenue Next Year | $11.40 | $408.85 |
| P/E Ratio | $49.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.12 | $12.58 |
| 52 Week High | $85.83 | $27.30 |
Technical Indicators
Market Signals| Indicator | COCO | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 52.33 |
| Support Level | $65.11 | $22.32 |
| Resistance Level | $69.59 | $25.74 |
| Average True Range (ATR) | 2.61 | 0.90 |
| MACD | 0.17 | 0.06 |
| Stochastic Oscillator | 52.29 | 59.84 |
Price Performance
Historical ComparisonAbout COCO The Vita Coco Company Inc.
The Vita Coco Co Inc is a plant-based functional hydration platform. Its products include Vita Coco Coconut Water, Private Label including coconut water and oil, and Other including Runa, Ever & Ever, and PWR LIFT product offerings, Vita Coco product extensions beyond coconut water, such as Vita Coco Sparkling, coconut milk products, and others. The company has two segments: The Americas segment which comprises of operations in the U.S. and Canada; and The International segment that comprises of operations in Europe, the Middle East, Africa and the Asia Pacific regions. The Americas segment derives maximum revenue. Geographical presence of the company is in United States, United Kingdom and All other countries.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.